InMode (INMD) Device Pricing and FDA Issues Case

• $INMD stockholder filed a claim vs. InMode over misleading them about device pricing, demand and FDA compliance.

• The news about financial issues caused $INMD to fall 25%, damaging shareholders.

On Feb 17, 2023, an investigation disclosed InMode threatening customers with legal action over device complaints.

• Customers reported being offered replacements in exchange for signing confidentiality agreements.

On this news, $INMD fell 3.27% on February 21, 2023, seriously damaging shareholders.

On October 12, 2023, InMode adjusted its revenue outlook due to higher costs and stricter leasing rules. A report later exposed price and profit discrepancies, showing big discounts on devices.

Due to this, $INMD dropped by 25.87% in the next two days.

Based on these events, $INMD stockholder filed a claim against InMode and its leaders, accusing them of the following:

• InMode supposedly lied about device pricing and demand, and misled about FDA compliance, including off-label marketing and injury reporting.

Considering all the information, investors might have grounds to suspect InMode of misleading over the device pricing and FDA compliance, which led to their losses.